" class="no-js "lang="en-US"> Julian Riba - Medtech Alert
Sunday, September 14, 2025

Breaking News

Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Astellas and Cullgen Enter into Strategic Collaboration and Option Agreement to Advance Innovative Targeted Protein Degraders Auxilius Pharma Raises Seed Funding of $1 Million and Commences its Clinical Program Captivate Bio and EverCell Bio partner on Human Cell Modeling Services for Cell and Gene Therapy Markets Applied StemCell Partners with CIRM to Provide Clinical-Grade iPSCs and Access to Its Proprietary Gene Editing Technologies Alentis Therapeutics Receives IND Clearance from FDA for ALE.C04 for the Treatment of CLDN1+ Tumors
Julian Riba

Julian Riba

About Julian Riba

Life science executive with experience in R&D, product management, and business development. Passionate about technology, entrepreneurship, and building great teams. Engineer by training with strong background in single-cell analysis, liquid handling, and molecular biology.

Related Story

News

 CYTENA Launches C.STATION

CYTENA Launches C.STATION, a Fully Automated Platform for Stable Cell Line Development to Streamline Production of Antibody and Gene Therapies

October 19 2021

Today CYTENA, a BICO company, launched C.STATION, a new platform for fully automated stable cell line development. The […]